Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;19(5):729-40.
doi: 10.1016/j.jasms.2008.02.008. Epub 2008 Mar 4.

A Novel Serine Phosphorylation Site Detected in the N-terminal Domain of Estrogen Receptor Isolated From Human Breast Cancer Cells

Affiliations
Free article

A Novel Serine Phosphorylation Site Detected in the N-terminal Domain of Estrogen Receptor Isolated From Human Breast Cancer Cells

David J Britton et al. J Am Soc Mass Spectrom. .
Free article

Abstract

Activated estrogen receptor (ERalpha) plays a critical role in breast cancer development and is a major target for drug treatment. Serine phosphorylation within the N-terminal domain (NTD) contributes to ERalpha activation and may also cause drug resistance. Previous biochemical identification of phosphorylated ERalpha residues was limited to protein artificially overexpressed in transfected cell lines. We report mass spectrometric methods that have allowed the identification of a new site within the NTD of ERalpha isolated from cultured human breast cancer cells. Immunoprecipitation, trypsin digestion, and analysis by nano-LC-ESI-MS/MS (Q-STAR, MDS Sciex) and vMALDI-MS(n) (Finnigan LTQ, Thermo-Electron) identified peptides containing 8 of 14 serine residues within the NTD, one being partially phosphorylated Ser-167, known but not previously reported by MS. Chymotrypsin digestion revealed other known sites at Ser-102/104/106 and 118. Tandem methods developed for the peptide containing Ser-118 and the use of hypothesis-driven experiments--i.e., the assumption that an intact phosphopeptide showing no molecular ion might yield fragment ions including loss of phosphoric acid in vMALDI-MS/MS--allowed the identification of a novel site at Ser-154. Quantitation by selected reaction monitoring demonstrated 6-fold and 2.5-fold increases in Ser-154 phosphorylation in estradiol- and EGF-treated cells, respectively, compared to controls, confirmed by immunoblotting with a novel rabbit polyclonal antibody. Thus, the protein isolation and MS strategies described here can facilitate discovery of novel phosphorylation sites within low abundance, clinically important cancer targets like ERalpha, and may thereby contribute to our understanding of the role of phosphorylation in the development of breast cancer.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111 - PubMed
    1. Mol Cell Biol. 1998 Apr;18(4):1978-84 - PubMed
    1. J Biol Chem. 2006 Aug 18;281(33):23686-97 - PubMed
    1. Breast Cancer Res Treat. 2003 Sep;81(1):81-93 - PubMed
    1. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S - PubMed

Publication types

LinkOut - more resources

Feedback